|
Market Cap | 7.67B | EPS (ttm) | -0.17 |
P/E | - | EPS this Y | 75.18% |
Forward P/E | - | EPS next Y | -12.97% |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 173.39 | EPS Q/Q | 95.68% |
Dividend | - | Sales Q/Q | - |
Insider Own | 88.18% | Inst Own | 7.12% |
Insider Trans | 0.04% | Inst Trans | -29.20% |
Short Float | 27.19% | Earnings | May 01/b |
Analyst Recom | 1.00 | Target Price | 7.50 |
Avg Volume | 2.56M | 52W Range | 1.50 - 5.39 |
|
|
|
Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Menlo Park, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Zanganeh Mahkam | Chief Executive Officer | Mar 27 '24 | Buy | 3.72 | 54,321 | 201,874 | 24,923,800 | Mar 27 08:28 PM | Zanganeh Mahkam | Chief Executive Officer | Mar 27 '24 | Buy | 3.72 | 26,000 | 96,720 | 520,814 | Mar 27 08:28 PM | Dhingra Ankur | Chief Financial Officer | Mar 26 '24 | Buy | 3.75 | 100,000 | 375,000 | 354,958 | Mar 27 08:27 PM | Zanganeh Mahkam | Chief Executive Officer | Mar 26 '24 | Buy | 3.75 | 30,000 | 112,500 | 30,000 | Mar 27 08:28 PM | Dhingra Ankur | Chief Financial Officer | Dec 13 '23 | Buy | 2.17 | 20,400 | 44,254 | 254,958 | Dec 13 04:49 PM |
|
|
|
|
Market Cap | 249.99M | EPS (ttm) | - |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 32.04 | EPS Q/Q | - |
Dividend | - | Sales Q/Q | - |
Insider Own | 45.38% | Inst Own | - |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 0.07% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 1.24M | 52W Range | 3.25 - 7.24 |
|
|
|
NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY. |
|
|
|
Market Cap | 2.84B | EPS (ttm) | 3.67 |
P/E | 5.89 | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 0.92 | EPS next 5Y | - |
P/B | 1.84 | EPS Q/Q | 12.91% |
Dividend | 11.59% | Sales Q/Q | 16.28% |
Insider Own | 46.67% | Inst Own | 29.30% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 0.08% | Earnings | May 30/b |
Analyst Recom | - | Target Price | - |
Avg Volume | 45.67K | 52W Range | 8.39 - 18.28 |
|
|
|
BW LPG Ltd. is an investment holding company, which engages in ship owning and chartering. It operates through the Shipping and Products Services segments. The company was founded in 1955 and is headquartered in Singapore. |
|
| |
|
Market Cap | 1.08B | EPS (ttm) | -1.01 |
P/E | - | EPS this Y | 7.29% |
Forward P/E | - | EPS next Y | 17.34% |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 41.44 | EPS Q/Q | 17.68% |
Dividend | - | Sales Q/Q | - |
Insider Own | 24.15% | Inst Own | 19.51% |
Insider Trans | 0.38% | Inst Trans | -9.29% |
Short Float | 4.64% | Earnings | May 10/b |
Analyst Recom | 1.40 | Target Price | 8.40 |
Avg Volume | 1.84M | 52W Range | 1.96 - 7.88 |
|
|
Today 08:00AM
|
Humacyte to Present at the Jefferies Global Healthcare Conference
(GlobeNewswire) +18.03% |
May-16-24 02:20PM
|
Hedge Fund and Insider Trading News: Michael Burry, Leon Cooperman, Ray Dalio, Stanley Druckenmiller, Millennium Management, Paulson & Co, Rokos Capital Management, Humacyte Inc (HUMA), GeneDx Holdings Corp. (WGS), and More
(Insider Monkey) |
May-13-24 08:00AM
|
Humacyte to Participate at Upcoming Investor Conferences in May
(GlobeNewswire) +16.60% |
May-10-24 02:43PM
|
Humacyte Inc (HUMA) Q1 2024 Earnings: Aligns with Analyst Projections Amid Strategic Advances
(GuruFocus.com) |
11:54AM
|
HUMA Stock Earnings: Humacyte Misses EPS for Q1 2024
(InvestorPlace) |
07:00AM
|
Humacyte First Quarter 2024 Financial Results and Business Update
(GlobeNewswire) |
May-06-24 08:00AM
|
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024
(GlobeNewswire) |
Apr-21-24 08:39AM
|
10 Stocks American Politicians are Buying in 2024
(Insider Monkey) |
Mar-26-24 04:05PM
|
Humacyte to Host Virtual KOL Event Hemodialysis Access: A Crossroads of Care, on March 28, 2024
(GlobeNewswire) |
Mar-23-24 10:16AM
|
Humacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Call Transcript
(Insider Monkey) |
|
Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Green Charles Bruce | Director | May 20 '24 | Option Exercise | 4.09 | 600 | 2,454 | 1,200 | May 21 04:08 PM | Wallace Max N. | Director | May 20 '24 | Buy | 6.25 | 8,005 | 50,030 | 4,015 | May 21 04:08 PM | Green Charles Bruce | Director | May 17 '24 | Option Exercise | 4.09 | 600 | 2,454 | 600 | May 20 04:11 PM | Binder Gordon M | Director | May 15 '24 | Buy | 6.78 | 50,000 | 339,000 | 160,000 | May 15 07:24 PM | Binder Gordon M | Director | May 15 '24 | Buy | 6.57 | 50,000 | 328,500 | 50,000 | May 15 07:24 PM |
|
|
|
|
Market Cap | 630.28M | EPS (ttm) | -0.38 |
P/E | - | EPS this Y | 500.00% |
Forward P/E | 54.50 | EPS next Y | 166.67% |
PEG | - | EPS past 5Y | - |
P/S | 4.33 | EPS next 5Y | 25.00% |
P/B | 4.46 | EPS Q/Q | 80.60% |
Dividend | - | Sales Q/Q | 32.40% |
Insider Own | 4.39% | Inst Own | 64.10% |
Insider Trans | -3.03% | Inst Trans | 1.14% |
Short Float | 5.36% | Earnings | May 29/a |
Analyst Recom | 1.00 | Target Price | 23.00 |
Avg Volume | 425.43K | 52W Range | 4.02 - 17.37 |
|
|
|
American Superconductor Corp. engages in the provision of megawatt-scale power solutions, which improve the performance of the power grid and lower the cost of wind power. It operates through the Grid and Wind segments. The Grid segment enables electric utilities and renewable energy project developers to connect, transmit, and distribute power with efficiency, reliability, security, and affordability. The Wind segment permits the manufacturers to field wind turbines with power output, reliability, and affordability. The company was founded by Yet Ming Chiang, David A. Rudman, John B. Vander Sande, and Gregory J. Yurek on April 9, 1987 and is headquartered in Ayer, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Kosiba John W JR | SVP, CFO & Treasurer | May 21 '24 | Sale | 14.82 | 29,000 | 429,814 | 348,136 | May 23 04:33 PM | McGahn Daniel P | Chairman, President and CEO | May 21 '24 | Sale | 14.82 | 20,559 | 304,741 | 1,057,121 | May 23 04:29 PM | McGahn Daniel P | Chairman, President and CEO | Jun 22 '23 | Sale | 5.95 | 36,902 | 219,596 | 1,077,680 | Jun 23 04:19 PM | Kosiba John W JR | SVP, CFO & Treasurer | Jun 22 '23 | Sale | 5.95 | 29,878 | 177,816 | 377,136 | Jun 23 04:15 PM | McGahn Daniel P | Chairman, President and CEO | Jun 21 '23 | Sale | 6.14 | 73,802 | 453,351 | 1,114,582 | Jun 23 04:19 PM |
|
|
| |
|
Market Cap | 37.53B | EPS (ttm) | 2.97 |
P/E | 12.94 | EPS this Y | 4.81% |
Forward P/E | 10.31 | EPS next Y | 8.28% |
PEG | 3.40 | EPS past 5Y | 0.02% |
P/S | 0.71 | EPS next 5Y | 3.80% |
P/B | - | EPS Q/Q | -42.89% |
Dividend | 2.89% | Sales Q/Q | -1.70% |
Insider Own | 0.22% | Inst Own | 78.74% |
Insider Trans | -10.46% | Inst Trans | -5.50% |
Short Float | 2.15% | Earnings | May 29/a |
Analyst Recom | 2.22 | Target Price | 34.46 |
Avg Volume | 7.33M | 52W Range | 25.22 - 33.90 |
|
|
Today | Reiterated |
TD Cowen |
Hold |
$30 → $32 |
|
Today 04:44PM
|
Why HP Stock Soared and Nearly Hit an All-Time High Today
(Motley Fool) +16.95% |
04:24PM
|
These Stocks Moved the Most Today: Salesforce, UiPath, HP Inc., Best Buy, Kohls, Foot Locker, C3.ai, Nutanix, and More
(Barrons.com) |
04:04PM
|
Heard on the Street: HPs OK Results Prove More than Enough
(The Wall Street Journal) |
04:03PM
|
HP Inc. Jumps Most Since 2015 Split on Renewed PC Sales
(Bloomberg) |
03:52PM
|
HP stock moves even higher on Q2 beat and PC demand
(Yahoo Finance Video) |
02:36PM
|
These Stocks Are Moving the Most Today: Salesforce, UiPath, HP Inc., Best Buy, Kohls, Foot Locker, C3.ai, Nutanix, and More
(Barrons.com) |
02:33PM
|
Stocks to Watch Thursday: Salesforce, Kohl's, Tesla, Dell
(The Wall Street Journal) |
12:53PM
|
Soft Q1 GDP, Salesforce falls, Dow shaves 300 points: Catalysts
(Yahoo Finance Video) |
12:43PM
|
Top Stock Movers Now: Salesforce, HP, Foot Locker, and More
(Investopedia) |
12:15PM
|
Salesforce, Agilent fall; HP, Foot Locker rise, Thursday, 5/30/2024
(Associated Press Finance) |
|
HP Inc. engages in the provision of personal computing and other access devices, imaging and printing products, and related technologies, solutions, and services. It operates through the following business segments: Personal Systems, Printing, and Corporate Investments. The Personal Systems segment offers commercial and consumer desktop and notebook personal computers, workstations, thin clients, commercial tablets and mobility devices, retail point-of-sale systems, displays and other related accessories, software, support, and services for the commercial and consumer markets. The Printing segment provides consumer and commercial printer hardware, supplies, solutions and services, and scanning devices. The Corporate Investments segment includes HP Labs and certain business incubation projects. The company was founded by William R. Hewlett and David Packard in 1939 and is headquartered in Palo Alto, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Bergh Charles V | Director | Apr 01 '24 | Option Exercise | 0.00 | 6,470 | 0 | 27,155 | Apr 03 05:01 PM | BENNETT ROBERT R | Director | Mar 21 '24 | Sale | 30.01 | 67,000 | 2,010,670 | 60,216 | Mar 22 05:08 PM | Liebman Stephanie | Global Controller | Mar 08 '24 | Sale | 30.93 | 8,708 | 269,338 | 0 | Mar 12 05:02 PM | McQuarrie David P. | Chief Commercial Officer | Mar 05 '24 | Sale | 29.19 | 51,111 | 1,491,930 | 5,449 | Mar 07 05:18 PM | Ludgate Kristen M | Chief People Officer | Mar 05 '24 | Sale | 29.24 | 41,015 | 1,199,279 | 56,169 | Mar 07 05:23 PM |
|
|
|
|
Market Cap | 294.28M | EPS (ttm) | -0.63 |
P/E | - | EPS this Y | 152.90% |
Forward P/E | 13.91 | EPS next Y | 28.24% |
PEG | - | EPS past 5Y | 26.89% |
P/S | 9.53 | EPS next 5Y | - |
P/B | 3.95 | EPS Q/Q | - |
Dividend | - | Sales Q/Q | - |
Insider Own | 2.90% | Inst Own | 0.15% |
Insider Trans | 0.00% | Inst Trans | 8.95% |
Short Float | 0.18% | Earnings | May 14/a |
Analyst Recom | 1.29 | Target Price | 10.19 |
Avg Volume | 8.24K | 52W Range | 2.89 - 5.24 |
|
|
|
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-Francois Mouney, Florence Sejourne, and Bart Staels in September 1999 and is headquartered in Loos, France. |
|
| |
|
Market Cap | - | EPS (ttm) | - |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | - |
Dividend | - | Sales Q/Q | - |
Insider Own | - | Inst Own | - |
Insider Trans | - | Inst Trans | - |
Short Float | - | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 260.65K | 52W Range | 12.95 - 13.95 |
|
|
|
|
|
Market Cap | 20.56B | EPS (ttm) | 0.28 |
P/E | 226.95 | EPS this Y | 9.87% |
Forward P/E | 33.92 | EPS next Y | 17.57% |
PEG | 12.82 | EPS past 5Y | - |
P/S | 7.01 | EPS next 5Y | 17.70% |
P/B | 15.91 | EPS Q/Q | 50.77% |
Dividend | - | Sales Q/Q | 17.68% |
Insider Own | 6.02% | Inst Own | 84.22% |
Insider Trans | -3.27% | Inst Trans | 3.18% |
Short Float | 3.46% | Earnings | May 29/a |
Analyst Recom | 1.52 | Target Price | 68.32 |
Avg Volume | 3.39M | 52W Range | 27.98 - 63.06 |
|
|
Today | Downgrade |
Northland Capital |
Outperform → Market Perform |
$58 → $68 |
Today | Reiterated |
TD Cowen |
Buy |
$60 → $80 |
|
Today 04:24PM
|
These Stocks Moved the Most Today: Salesforce, UiPath, HP Inc., Best Buy, Kohls, Foot Locker, C3.ai, Nutanix, and More
(Barrons.com) |
02:36PM
|
These Stocks Are Moving the Most Today: Salesforce, UiPath, HP Inc., Best Buy, Kohls, Foot Locker, C3.ai, Nutanix, and More
(Barrons.com) |
01:07PM
|
Q1 2025 Pure Storage Inc Earnings Call
(Thomson Reuters StreetEvents) |
08:26AM
|
Pure Storage (PSTG) Q1 Earnings & Revenues Beat Estimates
(Zacks) |
May-29-24 08:53PM
|
PSTG Stock Earnings: Pure Storage Beats EPS, Beats Revenue for Q1 2025
(InvestorPlace) |
06:30PM
|
Pure Storage (PSTG) Reports Q1 Earnings: What Key Metrics Have to Say
(Zacks) |
06:29PM
|
AI will put pressure on company spend but data storage 'will still be needed', says Pure Storage CEO
(CNBC TV) |
05:20PM
|
Pure Storage (PSTG) Surpasses Q1 Earnings and Revenue Estimates
(Zacks) |
04:47PM
|
Pure Storage's Earnings Beat Adds To Strong Run For Data Player
(Investor's Business Daily) |
04:17PM
|
Pure Storage: Fiscal Q1 Earnings Snapshot
(Associated Press Finance) |
|
Pure Storage, Inc. engages in the business of delivering innovative and disruptive data storage, products, and services that enable customers to maximize the value of data. The firm is also involved in the provision of data storage and management with a mission to redefine the storage experience by simplifying how people consume and interact with data. The company was founded by John M. Hayes and John Colgrove in October 2009 and is headquartered in Santa Clara, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Krysler P. Kevan | Chief Financial Officer | Apr 17 '24 | Sale | 52.80 | 15,286 | 807,101 | 507,824 | Apr 19 04:11 PM | FitzSimons Dan | Chief Revenue Officer | Apr 16 '24 | Sale | 52.14 | 29,283 | 1,526,816 | 138,105 | Apr 18 04:25 PM | Brown Andrew William Fraser | Director | Apr 15 '24 | Sale | 52.31 | 20,564 | 1,075,703 | 24,400 | Apr 17 04:27 PM | Dietzen Scott | Director | Apr 12 '24 | Sale | 53.49 | 147,000 | 7,863,030 | 100,000 | Apr 16 04:38 PM | Singh Ajay | Chief Product Officer | Apr 05 '24 | Sale | 53.54 | 37,588 | 2,012,462 | 380,834 | Apr 09 06:32 PM |
|
|
|
|
Market Cap | 8.47B | EPS (ttm) | -5.24 |
P/E | - | EPS this Y | 15.88% |
Forward P/E | - | EPS next Y | 12.96% |
PEG | - | EPS past 5Y | -4.82% |
P/S | 26.84 | EPS next 5Y | - |
P/B | - | EPS Q/Q | 9.69% |
Dividend | - | Sales Q/Q | 15.77% |
Insider Own | 3.00% | Inst Own | 100.61% |
Insider Trans | -13.82% | Inst Trans | -4.49% |
Short Float | 6.89% | Earnings | May 09/b |
Analyst Recom | 1.06 | Target Price | 59.44 |
Avg Volume | 2.47M | 52W Range | 18.31 - 53.98 |
|
|
|
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Flammer Martina M.D. | Chief Medical Officer | May 30 '24 | Option Exercise | 23.75 | 21,195 | 503,381 | 127,329 | May 30 05:43 PM | Flammer Martina M.D. | Chief Medical Officer | May 30 '24 | Sale | 55.00 | 21,195 | 1,165,725 | 106,134 | May 30 05:43 PM | Bonstein Sara | Chief Financial Officer | May 29 '24 | Option Exercise | 26.57 | 220,564 | 5,861,212 | 358,769 | May 30 05:41 PM | Bonstein Sara | Chief Financial Officer | May 29 '24 | Sale | 50.00 | 220,564 | 11,028,200 | 117,481 | May 30 05:41 PM | Flammer Martina M.D. | Chief Medical Officer | May 28 '24 | Option Exercise | 23.66 | 103,806 | 2,456,050 | 209,940 | May 30 05:43 PM |
|
|
|